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I 
Riassunto 
 
L’ Iperlipidemia Familiare Combinata (FCHL) è una patologia 
complessa caratterizzata da elevati livelli sierici di colesterolo e 
trigliceridi, e riscontrata nel 20% dei pazienti con disturbi coronarici. I 
pazienti affetti da FCHL presentano inoltre insulino resistenza, obesità 
e ipertensione. Sono stati condotti diversi studi per la comprensione 
del meccanismo melecolare e genetico dell’FCHL anche se non hanno 
portato ad una comprensione chiara ed esaustiva, e sono stati 
individuati alcuni geni, come USF1 (upstream trascription factor 1), 
LDL-R (LDL receptor), ApoA1 e CRABP-II (cellular retinoic acid-
binding protein 2), che potrebbero giocare un ruolo importante nella 
rete di geni coinvolti nell’FCHL. 
La nostra attività sperimentale è stata improntata all’analisi dei 
profili di espressione genica in un gruppo di pazienti affetti da FCHL, 
mediante la tecnica dei DNA microarrays, allo scopo di individuare 
reti di geni coinvolti nella patologia. Questo lavoro è stato condotto 
partendo RNA di 10 pazienti affetti da FCHL comparato con quello di 
5 controlli con un quadro lipidemico normale (esp. 10vs5), e di 7 di 
questi pazienti prima e dopo il trattamento con le statine (esp. 7vs7). I 
dati di espressione ottenuti sono stati analizzati mediante il software 
GeneSpring 7.3 and 9.0, che ha generato, per entrambi gli esperimenti, 
liste di geni la cui espressione risultava alterata in maniera 
significativa. Dall’intersezione delle liste di geni di entrambi gli 
esperimenti abbiamo ottenuto una lista finale di geni la cui 
II 
espressione risultava aumentata o diminuita nei pazienti affetti da 
FCHL e che cambiava in risposta al farmaco (statine), e alcuni di 
questi geni sono stati sottoposti a validazione mediante RT-qPCR. 
Abbiamo condotto un’analisi dettagliata dei geni la cui 
espressione risultava alterata seguendo tre strade: 
 1. Analisi di GeneOntology. 
 2. Analisi dei network. 
 3. Analisi dei promotori. 
 
L’analisi di GeneOntology per l’esp. 10vs5 mostra 
un’arricchimento, molto significativo (p-value 10-11) di una famiglia 
di geni coinvolti nel metabolismo energetico; nell’esp. 7vs7 risultano 
arricchiti, con una stringenza media, gruppi di geni coinvolti 
nell’organizzazione del citoscheletro, nella morfogenesi e nella sintesi 
dei composti eterociclici. 
L’analisi dei network mostra che la patologia maggiormente 
correlata con il nostro dataset di geni è l’artereopatia cardiaca, seguita 
da patologie di tipo epatico e renale, che sono complicanze tipiche 
della patologia. 
Infine, l’analisi dei motivi, condotta mediante l’utilizzo del 
software MEME (Multiple Em for Motif Elicitation), mostra la 
presenza di ipotetici motivi di regolazione, che sono stati poi 
sottoposti ad analisi in vitro ed in vivo per verificare la loro capacità di 
agire come regolatori dell’ espressione genica. Abbiamo effettuato 
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saggi EMSA (Electrophoretic Mobility Shift Assay) per vedere se 
questi motivi fossero in grado di legare proteine nucleari, e saggi di 
espressione transiente (CAT assays) per vedere se questi motivi 
fossero in grado di indirizzare l’espressione del gene reporter. Questi 
esperimenti hanno mostrato che, almeno uno di questi motivi, è in 
grado di agire come regolatore dell’espressione genica. Esperimenti di 
mutagenesi condotti sul motivo in esame hanno mostrato che la 
capacità regolatoria dello stesso è sequenza-specifica. 
Nel complesso questi dati suggeriscono l’ipoespressione di due 
network di geni, coinvolti nella produzione di energia e 
nell’infiammazione, e che potrebbero giocare un ruolo importante 
nell’FCHL. 
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Summary 
 
Familial Combined Hyperlipidemia (FCHL) is a complex 
disease characterized by elevated levels of serum total cholesterol, 
triglycerides or both, found in 20% of patients with coronary heart 
disease. FCHL patients are also affected from insulin resistance, 
obesity and hypertension. Several studies have been performed to 
understand molecular mechanisms and genetics of FCHL, but still 
nothing conclusive and exhaustive, although genes have been 
identified involved in disease, as USF1 (upstream trascription factor 
1), LDL-R (LDL receptor), ApoA1 and CRABP-II (cellular retinoic 
acid-binding protein 2), that may be part a important role in genes 
networks of FCHL. 
Our experimental activity has been focused to the analysis of 
gene expression profiles in a group of FCHL patients, using the DNA 
microarrays technique, to identify regulatory networks of genes 
involved in disease. We conducted a study starting  from RNA of 10 
FCHL patients compared with 5 normolipidemic controls (exp. 10vs5) 
and 7 patients by FCHL before and after treatment with statins (exp. 
7vs7). Expression data were analyzed using the software GeneSpring 
7.3 and 9.0, we generated a series of lists of genes, in both 
experiments, whose expression was changed significantly. By an 
intersection of the lists of both experiments we have obtained a final 
list of genes, whose expression is increased or decreased in FCHL 
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patients and that changes in response to the drug (statins), of which 
some were subject to validation by RT-qPCR. 
A main focus of my work has been to detailed analysis of the 
genes whose expression was altered through:  
1. Gene Ontology analysis. 
2. Network analysis. 
3. Motif analysis. 
Gene Ontology analysis in 10vs5 exp. showed highly significant 
enrichment (p-value 10
-11
) of a genes family involved in energy 
metabolism; in 7vs7 exp. are enriched, with medium stringency, 
groups of genes involved in the organization of cytoskeleton, 
morphogenesis and, synthesis heterocyclic compounds. 
Network analysis shows that the disease more related with our 
genes dataset is cardiac arteriopathy, closely followed by kidney and 
liver pathologies , also typical complications of the disease. 
Motif analysis, performed using the software MEME (Multiple 
Em for Motif Elicitation), shows some hypothetical motifs of 
regulation that we submitted to in vitro and in vitro experiments to 
verify their ability to act as regulators of gene expression. We 
performed EMSA assays (Electrophoretic Mobility Shift Assay) to 
test the ability of these “motifs” to bind nuclear proteins and transient 
expression assays (CAT assays) to show the ability of these motifs to 
drive expression of reporter genes. These experiments show that at 
least one of the motifs considered, its ability to act as gene expression 
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regulator. Mutagenesis experiments conducted on the motif 
considered showed that its regulatory function is sequence-specific. 
Taken together, our data suggest that the down-regulation of two 
main gene networks, respectively in Energy production and 
inflammation, may be an important feature of the FCHL syndrome. 
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1. Introduction 
 
1.1 System Biology 
The, discovery of the double helix structure of DNA, by Watson and 
Crick, opened the way, to the understanding of the molecular basis of 
various aspects of biology, like diseases, heredity, development, etc.. Since 
then, molecular biology has made giant steps with the sequencing of many 
genomes, from the most simple like that of E.coli, to the most complex as 
those of mouse, monkey and finally the completion of Human Genome 
Project at the beginning of the new millennium. These new knowledges are 
leading us to conceive the molecular machinery of a cell not as the sum of 
individual components, but as a complex of integrated and interrelated 
molecular functions, giving rise to a new branch of Biology, the Systems 
Biology. Systems Biology encompasses several research areas : from 
molecular biology to bioinformatics, and also involves numerous disciplines 
such as genomics, transcriptomics, proteomics, interactomics, etc.. 
Investigation areas of Systems Biology are (1): 
1. Structure systems analysis: it includes the interactions of genes, the  
biochemical pathways connecting them, the mechanisms of these 
interactions and how they modulate the physical structure of organisms. 
2. System dynamics analysis: the understanding of how a system acts in 
time, how it reacts to specific stimuli and its sensitivity. The use of 
theoretical analysis and computer simulations are essential for this kind of 
analysis. 
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3. Control methods analysis: it identifies the control mechanism necessary 
to minimize malfunctioning of the system. 
4. Systems design methods: the possibility to plan and construct biological 
systems with the desired properties through simulations. 
Progress in one of these four areas of Systems Biology requires 360° 
innovation  not only in molecular biology, but also in computational science 
and measurement technology, due to the high complexity of biological 
systems. The main goal of these approach is to identify the regulatory logic 
of genes and their biochemical networks. 
One main tool to understand the complex molecular systems is 
networks theory. A network is represented as a graph, where the objects 
(nodes) are connected together by different kinds of links. Special nodes, 
with a high number of links and connected to a large number of nodes, are 
called hubs. In a gene regulatory network, nodes and links represent the 
effect (activation or repression) exerted by a gene product on the activity of 
another, and Hubs represent the key points of networks. There are several 
methods to understand and analyze genes regulatory networks, based on 
different computational and mathematical methods (2,3), which combine 
gene expression data with the results of proteome, interactome (4) or 
promoter analysis (5). 
In these thesis, we will use the Ingenuity Pathway Analysis (IPA), one 
of the most commonly used tool for network analysis. 
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1.2 Familial Combined Hyperlipidemia (FCHL) 
The hyperlipidemias include a heterogeneous group of disorders, 
characterized by an high concentrations of cholesterol and/or triglyceride in 
the plasma (6,7). Familial combined hyperlipidemia (FCHL), which is the 
subject of the present study, is the most common genetic disorder associated 
with  premature cardiovascular disease (CVD), with an incidence of 1-3% in 
Western population. Familial combined hyperlipidaemia (FCHL) is a 
genetically complex lipid disorder, first recognised in 1973 by Goldstein et 
al, characterised by increased levels of plasma cholesterol or triglycerides in 
relatives of the same family. The intrafamilial variability of the lipid 
phenotype probably results from the interaction of multiple genes, some of 
which have been identified, with different environmental factors. 
Several metabolic abnormalities have been described in FCHL 
patients, including very low density lipoprotein and apolipoprotein B 
(ApoB) overproduction, the presence of small dense low density 
lipoprotein (sdLDL), increased production of apolipoprotein C III, insulin 
resistance and obesity. All of them may contribute to the increased 
atherosclerotic risk associated with such a condition. (8). 
Familial combined hyperlipidemia is a classic example of multigenic 
and multifactorial disease, occurring between second and third decade of 
life. Using the increase of VLDL, LDL, or both as a phenotype for family 
studies, Goldstein et al. (9) and Brunzell et al. (10), concluded that familial 
combined hyperlipidemia is an autosomal dominant condition with high 
penetrance. Brunzell et al.estimated that 10% of premature coronary artery 
disease is caused by FCHL (9,10). 
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FCHL patients synthesize and secrete increased amount of very low 
density lipoproteins (VLDL) in response to an increased flux of free fatty 
acids (FFAs) through the liver, which derives from the inability of adipose 
tissue of these subjects to incorporate FFA (11). The consequence of that is 
that FCHL patients present an interstitial accumulation of FFAs and pro-
inflammatory adipokines in the adipose tissue, which in turn to reinforces 
the metabolic dysfunction. 
Adipose tissue is one of the major contributors of free fatty acids 
(FFA) in the circulation. High levels of FFA in the circulation may lead to 
both a decrease in insulin-stimulated glucose uptake in skeletal muscle, and 
to an increase in hepatic lipoprotein synthesis, both characteristics of FCHL 
syndrome. Therefore, liver, adipose tissue, and muscle are interesting target 
tissues for differential gene expression studies (12). 
The role of inflammatory processes in FCHL is unclear, but there are 
many inflammatory markers associated with familial combined 
hyperlipidemia (FCHL), like vascular cell adhesion molecule-1 (sVCAM-
1), monocyte chemoattractant protein 1 (MCP-1), interleukin 6 (IL-6), 
tumor necrosis factor-α (TNF-α). The presence of these markers is 
independent from age, sex, body weight, insulin resistance, and metabolic 
syndrome (13). 
To clearly define a disease so complex as FCHL is quite difficult. 
There are two basic criteria to diagnosticate this pathology: 
1. Clinical: Findings of hypertriglyceridemia, hyperapobetalipoproteinemia, 
increased small and dense LDL (sdLDL) are crucial for FCHL diagnosis, 
however, non-essential but frequent characteristics as low plasmatic 
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concentrations of HDL, increased cholesterol, obesity and insulin 
resistance may help for diagnosis. 
2. Genetics: Several studies have been performed to understand the 
molecular mechanisms and genetics of FCHL, but there are no 
conclusive  answers yet. However, some genes involved in FCHL disease 
have been identified, as USF1 (upstream trascription factor 1), LDL-R 
(LDL receptor), ApoA1 and CRABP-II (cellular retinoic acid-binding 
protein 2) (14, 15, 16), may partecipate to genes networks that are 
affected in FCHL patients. 
It is now clear that the genetics of FCHL is complex and the 
phenotype is heterogeneous. It is possible that the heterogeneity of the 
FCHL phenotype arises from a defect in more than one gene or, 
alternatively, that the disorder results from the interaction between one or 
more major genes and their “genetic” environment (12). 
Recent trials show that high concentrations of small dense low-density 
lipoprotein (sdLDL) are highly specific markers of FCHL, independently of 
a concomitant metabolic syndrome (MS). In FCHL patients high levels of 
sdLDL are related to history of cardiovascular (CVD) events, independently 
of MS, total cholesterol and apo B (17). 
Due to insulin resistance and obesity concomitance, a first approach to 
FCHL treatment is the achievement of an ideal weight through a balanced 
diet (complex carbohydrates, monounsaturated fats, etc.). If the balanced 
diet fails and the lipidic profile is still altered, drug therapy may be used to 
normalize lipidic profile. The most used drugs are the “fibrates” for a 
hypertriglyceridemic phenotype, and the “statins” for a 
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hypercholesterolemic phenotype. In this study we focalized the attention on 
the effect of statins on FCHL disease.  
Statins act as inhibitors of the enzyme HMG-CoA reductase (3-
hydroxy-3-methyl-glutaryl-CoA reductase), an enzyme that plays a central 
role in the biosynthesis of cholesterol in the liver, blocking the conversion 
of HMG-CoA in mevalonate, a precursor of cholesterol (Figure 1). 
 
 
 
Figure 1: Cholesterol metabolism: the figure shows how the liver 
metabolism of cholesterol is  blocked  by statins, that inhibit the conversion 
of HMG-CoA in mevalonate, a precursor of cholesterol. 
 
Statins also act by increasing the expression of LDL receptors, 
promoting a greater uptake of plasmatic LDL by hepatocytes, therefore 
resulting in a reduction of cholesterol levels. 
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Literature evidence also suggest a pleiotropic effect of statins, 
probably connected to the inhibition of isoprenoids synthesis, requiered for  
prenylation of several important proteins associated to the plasma 
membrane (18). An important consequence is the inhibition of 
isoprenylation of small GTP-ase (or small G proteins) like Rho, Ras, Rac 
and Rap (13) and the consequent inhibition of enzyme NADP-oxidase, 
resulting in a reduced production of superoxide ions (free radicals), 
probably at the basis of the alleged anti-inflammatory action of statins. All 
these actions would result in plaque stabilization and the improvement of 
endothelial functions. 
Transcriptome analysis and gene expression profiles are a powerful 
tools for the identification of genes involved in complex diseases. This 
approach has already been used in several conditions, including diabetes 
mellitus (19), heart failure (20), and cancer (21), as well as in Tangier 
disease, a monogenic dyslipidemia (22). 
 
1.3 DNA Microarrays 
The main trend of the current postgenomic era, or the era of 
functional genomics is to expand the scale of biologic research from 
studying single genes or proteins to simultaneously studying all genes or 
proteins using a systematic approach. Among the methods for obtaining 
genome-wide mRNA expression data, DNA microarrays are particularly 
powerful since they can provide a global view of changes in gene expression 
patterns in response to physiologic alterations or manipulation of 
transcriptional regulators. 
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DNA microarray technology is a technique for comprehensive gene 
expression analysis and has been used in various fields, such as basic 
biology, medical science, and agriculture. In biomedical research, such an 
approach will ultimately define the transcriptional difference between 
normal and diseased tissues, which may provide insights into disease 
mechanisms and identify novel markers and candidates for diagnostic, 
prognostic and therapeutic intervention. However, microarray technology is 
still in a continuous state of evolution and development, and it may take 
time to implement microarrays as a routine medical device (23). 
DNA microarrays can be divided into 1) small custom arrays designed 
to monitor expression of a few hundred genes, 2) very large arrays that 
represent tens of thousands of genes, 3) arrays that represent entire 
genomes. Presently, there are several applications for DNA microarray-
based mRNA expression profile data, like the identification of genes whose 
mRNA levels are different under different biological conditions, e.g., in 
response to drugs treatments, in different cell types, or in particular mutants. 
Such genes are often considered candidates for playing an important role in 
the biological process of interest.  
Due to the size and complexity of mRNA profile data, computational 
tools are required for analysis. These tools must be tailored according to the 
type of analysis being carried out. If the goal is to identify genes that show 
differential expression among different samples, statistical tools for 
significance tests and multiple tests correction are needed to sort genes 
based on the degree of likelihood that they are actually differentially 
expressed (24). 
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Arrays, or DNA chips, are a collections of microscopic DNA spots 
attached to a solid surface (glass, plastic, nylon or silicon chips), each DNA 
spot containing a specific DNA sequence, the probes (in-vitro or in-situ 
synthesized). These sequences, often synthetic oligonucleotides, are 
complementary to a portion of the transcribed region of a gene, and are used 
to hybridize, under high-stringency conditions, cDNA samples (targets), 
representing the transcriptome. 
Oligonucleotide probes can be divided into two types: long (50 to 70 -
mer) and short (25 -mer). Long oligonucleotide probes are common among 
DNA microarrays produced in house and are used on some commercial 
DNA microarrays, but they offer poorer discrimination than short 
oligonucleotide probes. As the hybridization specificities of short 
oligonucleotides are lower than long ones, having multiple probes per gene 
is essential. It also provides an advantage as expression values can be 
calculated more precisely. 
Two-color and single-color methods: two-color or “two-channel” 
method is a procedure that analyzes two RNA samples on a single array, 
while a method that analyze one RNA sample on one array is called “single-
channel”, or one-color method. In two-channel methods, two mRNA 
samples are labeled with two different fluorochromes, typically Cy3 (green) 
and Cy5 (red), and the two labeled samples are competitively hybridized to 
a single array to obtain the ratio of the two mRNA levels. Since the array 
must be scanned at two wavelength channels because of the two different 
colors, this method is called “two-channel”. In contrast, in the one-channel 
method each cDNA is hybridized to one microarray slide, obtaining a single 
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dataset for each sample. In this case the comparison between the two 
samples is performed “in silico” by the data analysis software. The “two-
channel” method was initially developed because in the first spotted DNA 
microarrays the probe amounts could differ substantially from spot to spot. 
With the new commercial DNA microarrays the probe amounts are fairly 
homogenous, so the more robust single-channel methods can be used 
(Figure2).  
  
Figure2: “Two colours” (competitive) and “one colour” (single) 
procedures for cDNA hybridization on microarray slide. The data generated 
by the competitive procedure are expressed as ratio of fluorescence 
intensities, while those generated by the “one colour” approach are absolute 
intensity data. 
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There is a specific challenge to the two-channel method. While 
comparison of two samples hybridized to the same array can give good 
precision, comparison of two samples based on results of two arrays 
increases the error substantially, since two additional measured values are 
used in the calculation: To compare sample A and sample C based on the 
two sample ratios A/B and C/B, two sample B measurements are needed. 
Moreover, hybridizing all the sample pairs of interest would increase the 
number of arrays rapidly (25). 
After hybridization of the fluorescent targets to DNA microarrays, and 
washing to remove aspecific material, the array is scanned and fluorescence 
image of the array are generated. Data pre-processing consists of the 
procedures that convert the fluorescence image of the array into the 
expression level values for each gene of the array. The pre-processing 
methods are different for single-channel and two-channel methods, 
however, there are some common steps used in both methods. The measured 
fluorescence intensity values in each array must be corrected for the 
background, which is caused by optical noise, non-specific hybridization, 
probe-specific effects, and measurement error.  
Data from different arrays are usually not directly comparable even 
after background adjustment. For example, the overall fluorescence intensity 
among arrays typically varies. Ultimately, the goal is to compare the 
expression values of each gene from different arrays. The data from 
different arrays must first be “normalized”, so that they are comparable to 
each other. This “between-array” normalization is performed under certain 
assumptions. It is crucial that the assumptions made in a particular 
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normalization method are true for the data set of interest; otherwise, a 
normalization method can introduce artificial expression value changes. 
Common assumptions are that data from different arrays share the same 
value(s) of some descriptive statistics. The pre-processing and normalization 
procedures generate the expression data (dataset), that in a two-colours 
experiment are in form of expression ratios, while in a one-colour 
experiment consist in absolute intensity data. These data may then be 
subjected to further analysis, that are of two types: 
I level analysis. The generated dataset of different samples are 
grouped in “experiments”, in which two or more conditions are compared. 
Usually this analysis consists in a measurement of the expression changes 
(increase, decrease, no change) for each gene of the array in the two or more 
conditions being compared. In this step the extend of variations (fold 
change) and the statistical significance of the observed variations are 
assessed. The result of these analysis is usually a list of genes whose 
expression changes above or below a given threshold in a statistically 
significant way. 
II level analysis. These list of “altered” genes can be subject to further 
analysis, in order to evidentiate group of genes whose expression profiles 
are similar (hyerarchical clustering), or belonging to a gene category that 
results significantly enriched (Gene Ontology analysis), or to networks in 
which the occourrence of these genes that belong to the list is significantly 
higher than expected (network analysis). 
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The Gene Ontology (GO) project is a major bioinformatics initiative 
with the aim of standardizing the representation of gene and gene product 
attributes across species and databases (26). 
The project aims to: 
 the development and maintenance of the ontologies themselves; 
 annotate genes and gene products, and assimilate and disseminate 
annotation data; 
 development of tools that facilitate the creation, maintenance and use of 
ontologies. 
The ontology covers three domains: cellular component, molecular 
function and biological process. These three domains are composed of 
various sub-groups. This allows the user a subdivision of its genes list of 
analysis with different levels of specificity. Each domain, group and sub-
group have a special symbol that will identify it. 
In our study, we have performed all these analysis, and in addition we 
have carried out the search of putative DNA regulatory sequences in the 
promoters of these genes. 
A key step of all studies of gene expressions is validation to confirm 
the obtained data. The principal methods used are: qRT-PCR and Northern 
blot. 
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2. Materials and Methods 
 
My research activity has been directed to analyze the expression 
profiles of FCHL patients compared to that of normolipidemic controls, and 
that of the same patients after treatment with statins. 
Patients were selected by the team of Professor Paolo Rubba, Department of 
Clinical and Experimental Medicine University of Naples “Federico II”. 
Out of 27 FCHL patients provided by the clinical team, we have selected 10 
in order to minimize age (45-55) and severity of disease (middle) 
heterogenicity in the patients. We have therefore analized a group of 10 
FCHL patients and compared their expression profiles with those of 5 
normolipidemic controls  (Exp. 10 vs. 5). A second experiment has been 
carried out with a group of 7 FCHL patients before and after treatment with 
statins. 
 
2.1 RNA extraction 
RNA extraction was performed starting from lymphocytes of selected 
patients with 30 ml of blood according by using the Qiagen RNeasy midi-
extraction kit. Erytrocyte were lysed by the Qiagen EL buffer. RNA was 
then subjected to spectrophotometic quantitation and qualitative analysis 
through electrophoresis on formaldehyde agarose denaturing gel (FA). 
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2.2 DNA Microarrays 
RNA samples extracted and purified were sent to the genomic service 
“Genecore” of the European Molecular Biology Laboratory (EMBL, 
Heidelberg, Germany), where they were subjected to hybridization, 
scanning and pre-normalization, using a single hybridization procedure 
(“one color”) on CodeLink glass slides containing 56,000 oligonucleotides 
(60 bp) complementary to human transcribed sequences. 
The samples subjected to microarray analysis were then analysed into 
two experiments: 
-  10 vs 5: 10 FCHL patients compared to 5 healthy controls; 
-  7 vs 7: 7 FCHL patients before and after treatment with statins 
(atorvastatin). 
 
2.3 Data analysis: GeneSpring GX 7.3 software 
Datas resulting from array scanning were subjected to pre-
normalization using the analysis software CodeLink slides, and then 
organized in two different experiments “in silico”: 
 10 vs 5: to analyze the changes of the transcriptome associated with the 
disease. 
 7 vs 7: to analyze the changes of the transcriptome after treatment with 
statins. 
The analysis procedure used is identical in both experiments. 
The pre-normalization was performed by using the GeneSpring GX 
7.3 analysis software of Agilent Technologies. Normalization phase was 
carried out using the default parameters of the software that normalizes the 
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total intensity of the sample "for Genes" and "for Chip", whereby it is 
assumed that all samples have an equal amount of starting mRNA. A filter 
to prevent a high number of false positives axcludes all the genes whose 
value was <0.01001, thus filtering off all the negative samples, to which the 
scanner assignes a default value of 0.01. First-level analysis of the dataset 
consisted in two main analytical procedures:  
 Fold Change (FC): a filter that excludes those genes whose ratio between 
the expression values in the two conditions (FCHL vs. control in 10 vs 5; 
before and after treatment with statins in 7 vs. 7) is ≤ 2 or ≥ 0.5, in order 
to retain only those genes whose expression is increased or decreased by 
a factor 2. 
 Anova (analysis of variance): performed on the genes lists already 
filtered by Fold Change. This analysis calculates the variance among the 
different measurements of each gene in a given group (ex. FCHL) and 
compares it with the variance obtained for the same gene of another 
group (ex. controls) determining whether the differences between the two 
variances are statistically significant, with a cutoff of p-value ≥ 0.05. 
The first-level analysis generated two lists of hypo- and hyper-
expressed genes, one for each experiment (see results). 
Using a tool provided by the GeneSpring software (Venn diagrams) 
we then performed an intersection between the lists of two experiments 
"[10v5] ∩ [7v7]", generating a final list of 41 genes whose expression is 
altered in both experiments (see results). 
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2.4 Gene Ontology 
We then submitted the lists from the two experiments to GO analysis 
in order to identify genes groups belonging to GO categories and 
subcategories, which are significantly enriched (p-value ≤ 0.05) . 
For this analysis we used both the Gene Ontology tool provided by the 
GeneSpring software and a public domain tool, GOrilla (Gene Ontology 
enRIchment anaLysis and visuaLizAtion tool), which provides an output of 
Gene Ontology analysis in the form of DAGs (Direct Acyclic Graphs) 
simple and informative graphical representation (27). 
 
2.5 Network analysis 
We submitted the final lists of genes to IPA software (Ingenuity 
Pathway Analysis), a biological data analysis software from Ingenuity
®
 
Systems, which analyzes data from a variety of experimental platforms and 
provides accurate biological insight into the interactions between genes, 
proteins, pathways, cellular phenotypes, and disease processes in specific 
systems. 
We were especially interested in analysing with this software the 
genes lists of the 10 vs 5 experiment, to establish if there are associations 
between this genes and pathological conditions related to FCHL that could 
corroborate the reliability of our experimental dataset. 
 
2.6 RT-q PCR 
The most commonly method used for microarrays data validation is 
qRT-PCR technique. 
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Reverse Trascriptase: Starting from RNA of both experiments, we 
prepared c-DNA sample to be used in pPCR reaction. For each sample we 
started with 10 μg of total RNA using 200U of M-MLV RT for each μg of 
RNA (Invitrogen ®) using Invitrogen protocol. 
Primers: For each gene subject to validation was synthesized, at the 
oligonucleotides service of CEINGE-Advanced Biotechnology of Naples, a 
pair of 20bp primers, with a Tm (melting temperature) of 60° C and allowed 
to amplify a region of ≈ 200bp corresponding to the center of the transcribed 
region to be analized. 
PCR: To test oligonucleotides and the presence of homogeneous 
amplification we performed qualitative PCR reactions using Taq DNA 
polymerase (EuroClone ®) following the EuroClone protocol. Based on this 
screening, five pairs of primers were excluded from the final analysis of 
"Real-Time" PCR due to absence of amplification signal, or heterogeneity, 
of the amplified DNA. 
qPCR: Validation was then performed on 11 genes, starting from 100 
ng of c-DNA using 11 primer pairs plus a pair of primers for the Abl gene 
as an internal control. 
qPCR was performed with the SYBR Green method, using iQ SYBR 
Green Supermix enzyme of BioRad®. 
qRT-PCR consists of two main steps: 
 Denaturation at 90°C. 
 Annealing and extension at 60°C. 
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The samples were subjected to 40 amplification cycles. To check the 
efficiency of primers we used a tool of the I-Cycler software which 
measures the "Melting Curves" of the sample, allowing us to pinpoint 
heterogeneous amplificates. 
Two RNA samples from each patients or control were analysed, and 
each measurement was performed in triplicate. Therefore, each gene was 
analysed 10x2x3= 60x in FCHL patients and 30x in controls. 
The qPCR analysis allows the identification of the cycle where the 
fluorescence exceeds the background. This cycle is called "threshold cycle" 
(Ct). The difference between the Ct value of the sample of interest (the 
average of the 2x3 measurements) and the housekeeping gene (Abl gene) 
gave us the ΔCt value. The next step is the comparison of the expression 
levels in the two conditions (ex. Ct of FCHL gene less Ct of control gene), 
obtaining the ΔΔCt. Finally, everything is expressed as a negative 
exponential in base two to get the value of Fold Change: FC= 2
- ΔΔCt
. 
 
2.7 Motif analysis (MEME) 
The analysis of the promoters of our genes in order to identify putative 
regulatory sequences was carried out with the help of the software on-line 
MEME (Multiple Em for Motif Elicitation), which uses an algorithm that is 
able to identify, within a set of user-supplied data, short sequences which 
are over-represented significantly. 
We performed this analysis with the 41 genes resulting by the 
intersection of the lists of the two main experiments [ (10vs5) ∩ (7vs7) ]. 
We uploaded into the program the promoters sequences (FASTA format) of 
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the intersection gene lists in an ranging from -400 to +1 relative to 
trascription start site, setting the parameter “length of motifs” to 6-15bp. For 
the other parameter, like repetitions number, sites number and maximum 
number of searched motifs the default settings are used. The output of the 
software, both graphical and tabular, provides the following informations: 
 Motifs sequences, with a core and flanking sequences. 
 E-value of identified motif in the set of genes, gives by the sum of p-
values of the motif of the individual genes, an important information 
about the significativity of the motif. 
 Preservation of identified motif in the set of genes and its position 
(comparison matrix). 
This software also enables to compare the motifs found with the 
binding motifs for transcription factors already present in databases such as 
Jaspar and Transfac, using the TOMTOM tool. 
 
2.8 Nuclear extracts 
Nuclear protein extraction was performed starting from HepG2 cells 
(Hepatocellular carcinoma) using the Mini Dignam protocol (28): 
 Cell coltures at 80% confluence were harvested using a cell scraper, 
washed in 30 volumes of phosphate-buffer-saline (PBS), centrifuged for 
5 minutes at 1.200 rpm, resuspended in 1 volume of buffer A (10 mM 
Hepes pH7.9, 1,5 mM MgCl2, 10 mM KCl, 0,5 mM DTT) for lysis and 
incubated 15 minutes on ice. Cells were then lysed by 5-10 rapid strokes 
through a narrow gauge hypodermic needle (25-g ⅝).  
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 The cell homogenate is centrifuged for 20” at 12.000 rpm, the nuclear 
pellet is resuspended in 2/3 V of Buffer C (20 mM Hepes pH7.9, 25% 
Glycerol, 420 mM NaCl, 1,5 mM MgCl2, 0,2 mM EDTA, 0,5 mM 
PMSF, 0,5 mM DTT, 1% Aproteinin) and incubated on ice with stirring 
for 30 minutes.  
 The nuclear debris are then pelleted by spinning for 5 minutes at 12.000 
rpm and the supernatant (nuclear extract) can be stored at -80°C. The 
concentration of nuclear extract eas determined with the “Bio-Rad 
Protein Assay” based, on Bradford method (29). 
 
2.9 EMSA 
EMSA assay (Electrophoretic Mobility Shift Assay) is one of most 
used methods to study sequence-specific interactions between DNA and 
proteins. This assay requires the use of a terminally labeled DNA fragment  
which is interacting with the proteins of interest (in our case a crude extract 
of nuclear proteins). If the protein recognizes the binding site to the DNA 
fragment it binds and we observe a delay in electrophoretic migration of the 
DNA fragment due to the binding protein (or mixture of proteins) 
significantly delayes the bound DNA compared to the same unbound DNA 
fragment. 
Oligonucleotides synthesis:  
MEME analysis allows to identify a series of "motifs" present in the 
genes of our interest. We designed and sinthetized a pair of complementary 
DNA oligos containing the identified motifs. Two version for each 
sequence, based on the most conserved flanking region of the genes 
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containing the motif, were chosen and sintetized. The two olinucleotides 
(25bp) were designed so as to have, after annealing of the complementary 
sequences, a 5'-GATC- single strand sequence at both ends, such as to 
permit their use  in the experiments later described. The oligonucleotides 
were synthesized at the oligonucleotides service of CEINGE-Advanced 
Biotechnology of Naples. 
 
Oligo 1: 5’-GATCGTAGCTGGGCGTGGTCGGGTC-3’  
             3’-CATCGACCCGCACCAGCCCAGCTAG-5’ 
Oligo 2: 5’-GATCGCTCCTGGGGGTGTTCGGGGT-3’  
             3’-CGAGGACCCCCACAAGCCCCACTAG-5’ 
Oligo 3: 5’-GATCGCAGCTCTTTGCTTTGACAGA-3’  
             3’-CGTCGAGAAACGAAACTGTCTCTAG-5’ 
Oligo 4: 5’-GATCGGAGCTCTTTCCTTAGTTTGT-3’ 
             3’-CCTCGAGAAAGGAATCAAACACTAG-5’ 
Oligo 5: 5’-GATCAAGATGAATTTCAGCAGGACC-3’ 
             3’-TTCTACTTAAAGTCGTCCTGGCTAG-5’ 
Oligo 6: 5’-GATCCTGAAGAATTTCTGAAACAAG-3’  
             3’-GACTTCTTAAAGACTTTGTTCCTAG-5’ 
 
Labeled of probes using fill-in: 
This reaction allows the labeling of the 3’ termini of each filament of 
double-stranded DNA using the Klenow fragment of E. coli DNA 
polymerase I. 
The labeled protocol is the following: 
- 1 μg of dsDNA 
- Appropriate Buffer for Klenow fragment 
- 2 μCi ( 2000 Ci/mmole) of [α-32P] dATP 
- 10 Units of  Klenow fragment of E. coli DNA polymeraseI, incubated for 
45 minutes at room temperature.  
- Stop the reaction by heating it for 5 minutes at 70°C. 
- Separate the labeled DNA from unincorporated dNTP by 
chromatography on small columns of Sephadex G-50. 
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- Apply the radioactive probe (200 μl) to the top of G50 column. Fill the 
column with TE 1X buffer. 
- Start to collect fractions ( ≈ 200 μl) in microfuge tubes, measuring the 
radioactivity in each tubes. The leading peak of radioactivity consists of 
nucleotides incorporated into DNA, and the trailing peak consists of 
unincorporated [α-32P] dATP. 
- Pool the radioactive fractions in the leading peak and store at -20°C. 
- Alternatively, use a spin-column procedure. 
 
DNA Fragment Retardation Assay: 
3000 cpm of the endlabelled probe are incubated with the nuclear 
extract of interested ( ≈15 μg) and the appropriate buffer (10X binding 
buffer; buffer D). As carrier are used 100-300 μg/ml of poly [dI/dC]. The 
sample are incubated at 25°C for 25 minutes and 5 minutes on ice. After 
incubation are added the appropriate volume of loading buffer and the 
samples are loaded onto a 5% (29:1 Acrylamide/Bis-Acrylamide) native 
polyacrylamide gel. Electrophoresis is carried out in 1X TBE buffer at 
10V/cm for ≈ 2-3h. After electrophoresis the gel is dried with a gel dryer 
and exposed on Bio-Rad Imaging Screen K. After exposure, image is 
acquired by scanning with Bio-Rad phosphor-imager. 
Buffer conditions: 
10X Binding Buffer (BB): 
 1M KCl 
 20mM MgCl2 
 40mM Spermidine 
 1mg/ml BSA 
 
Buffer D: 
 20mM Hepes-KOH pH 7.9 
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 20% Glycerol 
 20mM KCl 
 2mM MgCl2 
 0.2mM EDTA 
 0.5mM DTT 
Loading buffer: 
 40% Glycerol 
 5x TBE pH 8.3 
 50mM EDTA 
 Bromophenolblue 
 
2.10 Preparing the plasmids for transient expression assays 
The oligonucleotides used in EMSA experiments were also used to 
perform transient expression assays in human cells, to determine if these 
motifs are capable to act, in vivo, as regulators of transcription. 
After annealing the oligonucleotides are cloned into a expression 
vector as monomers or polymers. The vector used is pTKsh-CAT (4421 bp), 
in which reporter gene (CAT gene), coding for enzyme Cloramfenicol 
Acetyl Transferase, is located under the control of a minimal promoter 
(SP1+TATA) derived from the Thymidine Kinase gene of Herpex Simplex 
Virus (HSV-TK). Upstream of the promoter is located the pUC19 
polylinker, that has many unique restriction sites, including the BamH1 site 
whose sticky ends are complementary to the ss extremities of our oligos. 
After oligos annealing we performed a phosphorylation reaction, to add a 
phosphate group at the 5 ' of oligos with the enzyme polynucleotide kinase 
T4, that catalyzes the transfer of terminal phosphate (γ) from ATP to the 5'-
OH of our ends oligos. pTKsh-CAT was digested with BamH1 restriction 
enzyme, purified on low-melting agarose gel and treated with alkaline 
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phosphatase CIP (Calf Intestinal Phosphatase) to remove 5' phosphate of 
vector to avoid closing of the empty digested vectors. 
We then performed a ligase reaction between vector and oligos, in a 
1:1 ratio, using T4 DNA ligase,. Ligase reaction DNA mixture was then 
inserted, by transformation, into "competent" bacterial cells of E. coli, strain 
DH5α, to assumption of exogenous DNA. DNA from picked positive 
colonies was extracted by QIAprep ® Spin Miniprep Kit using Qiagen 
protocol. 
To verify if the fragment of interest was inserted in properly we 
digested the mini-preps of plasmid DNA with the restriction enzyme Pst1, 
which cuts into our vector upstream and downstream of the BamH1 site, 
used to cloning DNA fragment. DNA presenting insert were sequenced at 
the sequencing service of CEINGE-Advanced Biotechnology of Naples. 
 
2.11 Transient expression assays 
Calcium phosphate transfection:  
Transfection was performed in two eukaryotic cell lines: HeLa and 
HepG2. The cells are grown at 37°C and 5% of CO2 in DMEM (Dulbecco's 
Modified Eagle Medium, Gibco) culture medium, supplemented with fetal 
bovine serum (FBS 10%), antibiotics (penicillin/streptomycin 1%) and L-
glutamine (1%).  
Transfection was performed using the DNA co-precipitation with 
calcium phosphate technique. Each sample was transfected in duplicate. 
Cells were trypsinized and cells are resuspend in the amount of DMEM 
desired, distributed in the plates, and incubated for approximately 3 hours 
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before transfection. 5 μg of DNA are transfected in each plate (6cm 
diameter), using the calcium phosphate methods (30) and incubate O/N. 
After 12-16 hours transfected cells are washed with PBS-EGTA (3 mM) in 
order to remove the precipitate that did not enter the cells and that may be 
toxic and supplemented with fresh culture medium. After 24 hours the cells, 
washed with PBS, are harvested by adding directly to the plate a solution 
containing 40 mm Tris pH 7.6, 1 mM EDTA, 150 mM NaCl (Ten solution). 
After incubating for 5 minutes at room temperature, the cells are collected 
by pipetting, centrifuged at 13,000 rpm for 1 minute (4 °C) and the cell 
pellet is resuspended in 200μl of 0.25 M Tris pH 7.8 (cold). The cells are 
then lysed by 4 cycles of freezing and thawing. After centrifugation for 10 
minutes at 13,000 rpm (4 °C) the supernatant containing cytoplasmic protein 
us collected and stored at -80 ° C. 
Chloramphenicol AcetylTransferase Assay (CAT assay): 
The chloramphenicol acetyltransferase (CAT) is a bacterial gene that 
encoding for an enzyme that neutralize the antibiotic chloramphenicol, by 
the addition of acetyl groups. This gene is not present in eukaryotes, 
therefore, eukaryotic cells-extracts do not show any background CAT 
activity. CAT gene is one of the first reporter genes used for transient 
expression experiments in mammalian cells. Important feature, of this 
system, is the extreme sensitivity of the assay and the absolute lack of 
background activity.  
CAT assays offer an indirect but quantitative way to measure the 
amount of transcription driven from any given promoter. 
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Introduction of putative regulatory sequences in vectors containing the 
CAT gene and transfection in cells culture allows to evaluate the ability of 
these sequences to drive the expression of CAT gene and therefore to act as 
transcriptional activators.  
CAT gene activity can be monitored using TLC (Thin Layer 
Cromatography), a chromatography based on distribution of different 
substances between a mobile (a mixture of solvents: chloroform-methanol 
19:1) and stationary (cellulose) phase. 
Protocol: 
 Heat at 37°C for 5 minutes a mixture with: 
        - 95 μl cellular extract 
        - 60 μl Tris 0.25 M pH 7.8 
        - 2.5 μl 14C-chloramphenicol (25 μCi) 
 Add 20 μl of 4 mM acetyl CoA 
 Keep at 37°C for 30 minutes 
 Extract with 500 μl ethyl acetate 
 Spin for 1 minute (4°) 
 Extract with another 500 μl ethyl acetate. Respin for 1  minute (4°) 
 Dry 1 ml in the Savant speed vac 
 Dissolve with 20 μl of ethyl acetate 
 Spot 20 μl on Polygram SIL-G thin layer chromatography sheet  
 Run the chromatography with 200 ml of  a (95:5) chloroform-methanol 
solution for 2h. 
 Dry the sheet on air 
 Expose to Bio-Rad Imaging Screen K. 
 Scanning image with Bio-Rad phosphor-imager. 
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3. Results 
3.1 First-level analysis 
First-level data analysis was performed using GeneSpring GX 7.3 
software of Agilent Technologies (see Materials and Methods), applying the 
Fold Change(FC) and Anova filter (Figure 3 a-b) to both 10vs5 and 7vs7 
experiments. For details, see Materials and Methods section 2.3, page 17. 
 
Figure 3a: Scatter plot of the experiment 7vs7 before and after FC filter 
 
Figure 3b: Scatter plot of the experiment 10vs5 before and after FC filter 
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This analysis generated two gene lists: a 1747 genes list, for the 
“10vs5” experiment  (1534 genes hypo-expressed and  213 genes hyper-
expressed), and a list of  460 genes for the “7vs7” experiments (296 genes 
hyper-expressed and  164 genes hypo-expressed). Using the GeneSpring 
“Venn diagrams” tool (Figure 4) we have intersected the two gene lists and 
generated a final list “[10v5]∩ [7v7]” (table 1) of 41 genes differentially 
expressed in both experiments (Figure 5). The two “main” list (10vs5 and 
7vs7) contain too many genes to be really useful. Therefore, any further 
discussion about these lists will be refered to the II-lvel analysis (GO, IPA 
and MEME). On the other hand, the “intersection” list contain a workable 
(41) number of genes, whose expression is altered in FCHL patients and 
restored upon statin treatment. Among these genes, there are some 
noteworth cases: 
1. ATP11B, a class VI ATPase, hypoexpressed (0,07x) in FCHL patients, 
that recovers after treatment (9.16x). 
2. SLC25A37, a Fe++ carrier protein, which is heavily hyperexpressed (70x) 
in patients and promptly reduced by statins (0,008x) 
3. HNF1α, a liver-specific transcriptional regulator, repressed in patients 
(0,08x) and restored by statins (6,7x). 
 
 
 
Figure 4: Venn diagrams showing the intersection of two gene lists 
[10v5]∩ [7v7], resulting in a final list of 41 genes (see table 1). 
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Genbank  Description FC 10v5 FC 7v7 
NM_014243 
 ADAM metallopeptidase with thrombospondin 
type1 motif,3 0,387 3,178 
CD245683 Aquaporin 1 (Colton blood group) (AQP1) 0,265 3,318 
BI757158 ATPase, class VI, type 11B (ATP11B) 0,0715 9,159 
NM_033028 Bardet-Biedl syndrome 4 (BBS4) 4,307 0,157 
NM_030809 Cysteine-serine-rich nuclear protein 2 (CSRNP2) 30,48 0,0148 
NM_000716 
Complement component 4 binding protein, beta 
(C4BPB) 0,452 3,203 
NM_001257 Cadherin 13, H-cadherin (heart) (CDH13) 0,328 2,522 
NM_000076 
Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
(CDKN1C) 0,376 0,476 
NM_003663 CGG triplet repeat binding protein 1 (CGGBP1) 14,1 0,0487 
NM_000497 
Cytochrome P450, family 11, subfamily B, pp 1 
(CYP11B1) 0,377 2,752 
X62515  Heparan sulfate proteoglycan 2 (HSPG2) 0,41 2,013 
AI680974 WDR45-like (WDR45L) 3,157 0,16 
              NM_145258 2,608 0,473 
AA916572 Solute carrier family 25, member 37 (SLC25A37) 69,6 0,00837 
NM_002864 Pregnancy-zone protein (PZP) 0,066 7,033 
AF153482 Ribosomal protein L41 (RPL41) 10,37 0,0921 
NM_014412 Calcyclin binding protein (CACYBP) 0,00297 100,5 
BE265261 Solute carrier family 25 member 3 (SLC25A3) 0,00356 142,7 
NM_000545 HNF1 homeobox A (HNF1A) 0,0845 6,716 
NM_003394 
Wingless-type MMTV integration site family 
(WNT10B) 0,0963 10,35 
BM727911 Transcribed locus 70,35 52,69 
BE857924 Transcribed locus 51,82 25,61 
AI827457  3,553 16,56 
BC023640 Homo sapiens, clone IMAGE:4890344, mRNA 2,195 12,05 
BQ187437 Hypothetical LOC728804 (LOC728804) 2,044 11,71 
AK056249 CDNA FLJ31687 fis, clone NT2RI2005473 0,453 6,812 
AW295445 Transcribed locus 0,442 6,145 
AI732747 Transcribed locus 0,433 4,724 
AI365358 Transcribed locus 0,424 3,336 
AI376656 Transcribed locus 0,39 2,902 
AW139602 Transcribed locus 0,376 2,617 
CB047896 Transcribed locus 0,373 2,505 
AI744743 Transcribed locus 0,276 2,383 
BG151547 Transcribed locus 0,274 2,353 
AW445216 Transcribed locus 0,0904 2,274 
AA776532 Transcribed locus 0,0793 2,148 
AI652378 Transcribed locus 0,0652 0,467 
BF195078  0,0459 0,372 
AI809873  0,0321 0,357 
AW291006 
Small nucleolar RNA, H/ACA box 58 
(SNORA58) 0,0186 0,0155 
BX096208  0,00834 0,00908 
 
Table 1: The 41 genes differentially expressed in the intersection of 
the two experiments (10v5 and 7v7).    
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Figure 5: Workflow of I level data analysis of both experiments. 
 
 
3.2 Gene Ontology analysis 
We have submitted the gene lists of the two experiments to Gene 
Ontology analysis tools. Figure 8 reports the results obtained with the 
software on-line GOrilla (Gene Ontology enRIchment anaLysis and 
visuaLizAtion tool) that provides an output in form of DAGs (Direct Acyclic 
Graphs). Genes clusters significantly enriched have a more intense color 
based on p-value.  
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The analysis of the 10vs5 list shows that a group of 14 ATP synthase 
genes, involved in the transport of protons in the mitochondria, is 
significantly (p-value <10
-11
) enriched. (Figure 6).  
 
 
Figure 6: The DAG (Direct Acyclic Graphs) of the biological process 
GO category resulting from the analysis of the 10vs5 gene list. A group of 
14 genes, belonging to the ATP synthase family, is strangly enriched (p-
value <10
-11
). 
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Gene Ontology analysis of the 7vs7 list shows an enrichment of three 
groups of genes (p-value <10
-6
), respectively involved in cytoskeleton 
organization, morphogenesis and synthesis of heterocyclic compounds 
(Figure 7). 
 
 
Figure 7: The DAG (Direct Acyclic Graphs) of the biological process 
GO category resulting from the analysis of the 7vs7 gene list. There are 3 
group, of 4 genes, involved in cytoskeleton organization, morphogenesis 
and synthesis of heterocyclic compounds. 
Results 
35 
3.3 Pathway analysis 
The 10vs5 gene list has been subjected to pathways analysis by using 
the IPA (Ingenuity Pathway Analysis) software. The results can be 
summarized as follows:  
A)  The search for pathologies significantly associated to our list of  
genes, whose results are reported in figure 8, gave us as a result three 
pathologies well above the significativity treshold: cardiac, liver and renal 
disease. These pathologies correspond exactly to the three main 
complications of the FCHL syndrome, thus confirming that our expression 
profiles identify correctly the gene expression changes associated to the 
FCHL condition. 
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Figure 8: disease related to gene list of intersection (Ingenuity 
Pathway Analysis). 
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B) The search for metabolic pathways indicate that 4 out of the 5 
enzyme complex involved into mitochondrial electron transport are affected, 
in FCHL patients, in agreement with the gene-ontology data (Figure 9). 
 
 
 
Figure 9: Metabolic networks associated to 10vs5 gene lists. 
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C) Among the other regulatory pathways that are affected in FCHL patients 
there is a network connecting lipid metabolism inflammation and apoptosis, 
in which the heavily hyperexpressed SLC25A37 gene plays a pivotal role 
(figure 10). 
 
 
Figure 10: Networks of gene hypoexpressed in FCHL patients that are  
involved in energy metabolism, lipid metabolism, inflammatory molecules 
and apoptosis. 
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3.4 Validation 
Microarrays data have been validated by qRT-PCR technique. 
Validation was performed on 16 genes (table 2), some of them belonging to 
the intersection list of two experiments, other to the 10vs5 list, in particular 
those with extreme FC values. 
 
 
Gene Bank Common name Description 
AW938887 SIP Siah-interacting protein 
NM_016355 DDX47 DEAD (Asp-Glu-Ala-Asp) box polypeptide 47 
BE265261 
SLC25A
3 solute carrier family 25 , member 3 
BM727911 Transeq Transcribed locus 
NM_000006 
TNFRSF
21 tumor necrosis factor receptor superfamily, member 21 
NM_000545 TCF1 HNF1 homeobox A 
AF533922 
          HLA-
DQA1 major histocompatibility complex, class II, DQ alpha 1 
NM_000011 ZNF143 zinc finger protein 143 
NM_021104 RPL41 ribosomal protein L41 
NM_005546 ITK IL2-inducible T-cell kinase 
NM_000075 ALAS1 aminolevulinic acid synthase 1 
NM_000002 PIG3 tumor protein p53 inducible protein 3 
AF158747 
GALNT1
0 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) 
NM_00007 CXCL9 chemokine (C-X-C motif) ligand 9 
NM_002207 ITGA9 integrin, alpha 9 
BU675991 HRB2 HIV-1 Rev binding protein 2 
 
Table 2: Lists of the genes submitted to validation by qPCR. 
 
 
Five out of the 16 genes (PIG3, GALNT10, CXCL9, ITGA9 e HRB2) 
were excluded from the final step of validation because RT-PCR pre-
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screening gave negative results (amplified DNA band heterogeneous or 
absent). 
RT-qPCR  experiments resulted in the validation of the expression 
pattern of 7 out of the 11 genes analyzed, 5 hypo-expressed and 2 hyper-
expressed (Figure 11). We assumed as validated the expression pattern of a 
gene when the two methods, namely microarrays analysis and qPCR, gave 
the some qualitative (i.e. significantly hyper or hypo-expressed) results. 
However, quantitative data also show the same relative range of FC 
varitions. More than >60% of the genes analyzed were validated, in line 
with the results published in literature for similar experiments (31). 
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Figure 11: The Fold Change values of the 11 genes submitted to 
validation by qRT-PCR (blue) as compared to Microarrays Fold Change 
values (red): 7 out of 11 genes were validated (>60%). 
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3.5 Promoter  analysis 
Promoter analysis was performed “in silico” by MEME software 
(http://meme.sdsc.edu/meme/cgi-bin/meme.cgi). We submitted to the 
MEME software the 5’ flanking sequences (-400 to +1 from trascription 
start site) of the 41 genes of the intersection list. The putative “motifs” 
(Figure 12) were analysed with the CisRed software, and each “motif” was 
used as a query to search Jaspar and TransFac transcriptional regulatory 
element databases for similarity to known regulatory sequences. From these 
results, we selected 3 putative regulatory motifs (Figure 13), to be submitted 
to in vivo and in vitro analysis. 
 
  
Figure 12: Combined block diagram generated by MEME analysis for 
the -400/+1 regions of the promoters of intersection genes list [(10vs5) ∩ 
(7vs7)]. 
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Figure 13: Three putative regulatory “motifs”. The sequence of the 
original context in which these motifs have been found are shown (BOX). 
For each motif, two “versions” have been selected for oligonucleotide 
sinthesys. 
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3.6 EMSA analysis 
The oligonucleotides synthesized for each motif (two versions for 
everyone, see Mat. and Met. section), were used for in vitro analysis by 
EMSA (Electrophoretic Mobility Shift Assays), in order to verify their 
ability to bind proteins present in nuclear extract from different cell lines. 
All the oligonucletides were positive to EMSA assays (figure 14). 
 
 
Figure 14: EMSA assay showing that all putative motifs (A, B and C) 
present a retarded band when challenged with HepG2 nuclear extracts. 
Sample are loaded in presence (+) and absence (-) of protein extracts. 
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Figure 15 reports an EMSA experiment carried out with the A1 Motif, 
showing that the retarted band is specifically competed by increasing 
amount the same or a related (A2) unlabeled oligo, but not by a different 
sequence. These results show that the binding of protein present in the 
nuclear extract is sequence-specific. 
 
 
Figure 15: EMSA assay for Motif A1: the data show that in presence 
of molar excess of specific competitor (A1-A2: ≈ 200x) the retarded band 
disappears. This competition effect does not occours with the aspecific 
competitor (β-casein promoter oligo). 
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3.7 CAT assays 
In order to investigate whether the selected motifs were able to act as  
transcriptional activators, we performed a serie of transient expression 
assays, with expression vectors containing the CAT reporter genes under the 
control of single or multiple copies of these motifs (figure 16).  
 
 
 
Figure 16: Map of expression vector pTKsh-CAT, 4446 bp, that used 
to clone the motif (in the BamHI site). 
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DNA sequencing to verify number and orientations of the inserts was 
described in the Mat. and Met. section. Table 3 shows the results of the 
cloning experiments, while in figure 17 is reported a typical transient 
expression. 
 
 
 
 
Table 3: Copy numbers and orientation of oligonucleotides inserted in 
the pTKsh-CAT vectors.
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The results show that, in HepG2 cells, the constructs containing the motif 
A1 are significantly more active than the reference vector (pTKsh-CAT), 
and that this activity increases depending on the copy numbers (motif 
A1   >> motif A1 ). 
 
Figure 17: Transient expression assay of constructs containing one or 
more copies of motif A or B. The picture shows the autoradiography and the 
phosphor-imager quantization of a CAT assay. The CAT activity of the A1 
sample is significantly higher than that of the pTK control plasmid (HepG2 
cells). 
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3.8 Site-direct Mutagenesis of the A1 motif 
The results of transient expression assays show that the A1 motif is 
transcriptionally active in HepG2 cells. To prove that this effect is sequence-
specific and depends on the “CORE” motif of the A1 oligo we performed a 
site-directed mutagenesis analysis of motif A1 (Figure 18): 
 
 
 
 
Figure 18: The three mutant oligos for mutagenesis analysis of motif 
A1. The divergent arrows indicate the two halves of the palindromic 
sequence found in the motif A1. 
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The transient expression assays, reported in figure 19 a-b, show 
clearly that all the mutations affect the transcriptional activity of the 
sequence, reducing it at levels comparable (if not lower) to those of the 
pTKsh_CAT control. 
 
 
 
Figure 19a: Transient expression assay showing that all the mutations 
reduce drastically the transcriptional activity  of motif A1(in HepG2 cells). 
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Figure 19b: Transient expression assay showing that all the mutations 
reduce drastically the transcriptional activity  of motif A1(in HeLa cells). 
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4. Discussion 
 
The ultimate goal of this study was to identify groups of genes whose 
expression levels in FCHL patients are significantly altered as compared to 
those of normolipidemic individuals and within the same FCHL patients, 
after treatment with statins. We have generated two lists of genes, 
corresponding to the 10vs5 experiment (FCHL patients vs. controls: 1747 
genes) and 7vs7 experiment (FCHL patients before and after treatments with 
statins: 460 genes). The Intersection of the two experiments has generated a 
final list of 41 genes, mostly hypo-expressed in FCHL, that after treatment 
with statins regain the original levels of expression, switching, sometimes, 
from hypo- to hyper-expression. The expression profiles of 11 of these 
genes have been subjected to validation using the qRT-PCR tecnique. We 
have validated the expression patterns of 7 of the 11 genes analyzed, namely 
more than 60%, in agreement with what other authors find in similar 
experiments (31). We have confirmed the hypo-expression of the TCF1 
gene (HNF1 homeobox A), which encodes for the transcription factor 
HNF1α, a major regulator of hepatic differentiation TCF1 alteration appears 
to be associated with a reduction of the APO-lipoprotein M (ApoM), and 
thus to a reduction of HDL (32), a typical symptom of FCHL. We also 
found the hypo-expression of the SIP gene (Siah-interacting protein), 
involved in protein degradation, which results in a slowdown of protein 
metabolism and in the alteration of the ATP synthesis. This may result in 
the accumulation of fatty acids, causing the FCHL symptoms. Finally, we 
found a reduced expression of the HLA-DQ1 gene (major histocompatibility 
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complex, class II, DQ alpha 1), responsible for the activation of 
lymphocytes B, which alters the immune response mediated by this factor, 
that is also partially reduced in FCHL patients.  
These genes lists have been the starting material for a detailed analysis 
of the functional and regulative relationships between the genes whose 
expression was altered in FCHL patients or after statins treatment. 
Gene Ontology (GO) analysis highlights coherent groups of 
functionally related genes that are significantly enriched. Gene Ontology 
analysis of the 10vs5 list shows a group of 14 hypo-expressed genes, that 
belong to the ATP synthase family involved in the protons transport in the 
mitochondria and a group of genes involved in protein degradation. Gene 
Ontology analysis of the 7vs7 list shows three enriched groups involved in 
cytoskeleton organization, morphogenesis and synthesis of heterocyclic 
compounds, respectively. 
Network analysis showed clearly that the human diseases more related 
with our gene dataset are cardiac arteriopathy, consistent with the high risk 
of coronary heart disease in FCHL patients, closely followed by kidney and 
liver pathologies, typical complications of FCHL (Figure 10). 
The promoter analysis of genes belonging to enriched GO categories 
and to the intersection list allowed us to identify putative regulatory 
sequences possibly involved in the pathology and/or in response to statins. 
The most interesting of these putative regulatory motifs were selected for 
further experiments in vitro (EMSA assay) and in vivo (CAT assay) to 
verify their ability to act as regulators of gene expression. All the tested 
motifs are positive to in vitro analysis, and one of them (motif A1) is able to 
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act as a regulator of gene expression (as also shown by site-directed  
mutagenesis experiments). A search for possible homologies between the 
consensus sequence of motif A1 and the binding sites of known 
transcription factors in the TRANSFAC and JASPAR databases showed a 
significant homology to the sequence of the binding site of the transcription 
factor Ikaros, which encodes a family of proteins belonging to the 
superfamily of zinc finger (33) and that play an key role in the cholesterol 
absorption. Motif A1 also shows significant homology to the binding site of 
factor Lun-1, that mediates proteins ubiquitination, regulates cell cycle, and 
inhibits cell proliferation (34-35). 
Our future experiments will be directed in the following directions: 
• To analyze the expression profiles of the validates genes in higher 
numbers of patients. This will serve to consolidate a “panel” of genes 
whose altered expression can be used as diagnostic tools for FCHL. 
• To analyze the putative regulatory motifs identified in silico in their 
biological  context (endogenous  promoter). We are aware of the 
limitations of the transient expression experiments carried so far, and it is 
very likely that many of these motifs, while failing to activate a reporter 
gene, may still have an importante regulatory role in their original 
context. It is to be taken into account that our “in vivo” assay only 
reveals putative activatory elements, while it is not suitable, in its present 
form, to identify negative regulatory sequences. 
• Finally, we plan to search for and to, identify the transcription factor(s) 
that interact with the  regulatory motifs, identified “in silico”, and 
validated in expression assay. 
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